cell and gene therapy

R&D

Reuters Pharma USA – Lung-I Cheng

Cell and gene therapies continue to be hot topics in the pharma world this year, and some companies are responding to the new treatment modalities with new business units.

R&D

JP Morgan 2023 - Day 1

We’re preparing to start JP Morgan week with a busy day Monday, with day 1 of the Informa Biotech Showcase, including a dedicated mini-event on Cell and Gene Therapy in the morning.

R&D

With landmark approval, spotlight on cryogenic logistics int...

The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world.

Views & Analysis

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

New Cell & Gene Therapy Collective seeks to boost UK adoptio...

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to

Views & Analysis

Gene editing: beyond the hype

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Bayer buys cell & gene therapy firm AskBio for $4 billion

Bayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US biotech Asklepios BioPharmaceutical, also known as AskBio.